Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.

Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.

Abstract: This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.

Abstract: This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.

Abstract: This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.

Abstract: Disclosed are methods for making a surface modified biomedical device involving (a) exposing a biomedical device having a plurality of biomedical device surface functional groups to one or more ethylenically unsaturated-containing organic compounds having a reactive group that is co-reactive to the biomedical device surface functional groups of the biomedical device; and (b) graft polymerizing a hydrophilic reactive monomer having a complementary reactive functionality with the ethylenically unsaturated functionalities of the ethylenically unsaturated-containing organic compounds on or near the surface of the biomedical device thus forming a biocompatible surface on the biomedical device. The methods disclosed are two-step methods and do not include any additional surface treatment steps.

Abstract: The present invention is directed to new and improved packaging systems for storing ophthalmic devices such as contact lenses and to methods for packaging such ophthalmic devices with aqueous packaging solutions to improve the comfort of the lens during wear. In particular, the present invention is directed to a packaging system for storing an ophthalmic device in an aqueous packaging solution comprising an anionic polymer and a non-ionic polyol. Such solutions can be retained on the surface of an unused lens for extended periods of time, resulting in surface modification that persists in the eye, which may provide significant improvement in the wetting properties of fresh contact lenses used for the first time and, moreover, even several hours after lens insertion, preventing dryness and improving lubricity.

Abstract: A method for treating a surface of a fluorinated silicone-containing ophthalmic device is provided, the method comprising plasma treating the fluorinated silicone-containing ophthalmic device with a hydrogen-containing atmosphere in the presence of an oxidizing source thereby increasing the wettability and/or biocompatibility of the device.

Abstract: A method for treating the surface of a fluorinated biomedical device is provided comprising the steps of (a) plasma treating the fluorinated biomedical device with a hydrogen-containing atmosphere to reduce the fluorine or C—F bonding content of the fluorinated biomedical device; and (b) subjecting the hydrogen plasma treated surface to a plasma-polymerization reaction in a hydrocarbon-containing atmosphere to form a polymeric carbonaceous layer on the surface of the biomedical device.